S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

NASDAQ:REXNRexahn Pharmaceuticals Stock Price, Forecast & News

$2.58
+0.01 (+0.39 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.48
Now: $2.58
$2.60
50-Day Range
$2.55
MA: $2.81
$3.00
52-Week Range
$1.26
Now: $2.58
$4.26
Volume35,725 shs
Average Volume202,755 shs
Market Capitalization$10.37 million
P/E RatioN/A
Dividend YieldN/A
Beta0.98
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REXN
CUSIPN/A
Phone240-268-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.48 per share

Profitability

Net Income$-8,640,000.00

Miscellaneous

Employees10
Market Cap$10.37 million
Next Earnings DateN/A
OptionableOptionable
$2.58
+0.01 (+0.39 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REXN News and Ratings via Email

Sign-up to receive the latest news and ratings for REXN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rexahn Pharmaceuticals (NASDAQ:REXN) Frequently Asked Questions

How has Rexahn Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Rexahn Pharmaceuticals' stock was trading at $1.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, REXN shares have increased by 35.1% and is now trading at $2.58.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Rexahn Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rexahn Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Rexahn Pharmaceuticals
.

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.34.
View Rexahn Pharmaceuticals' earnings history
.

When did Rexahn Pharmaceuticals' stock split? How did Rexahn Pharmaceuticals' stock split work?

Rexahn Pharmaceuticals shares reverse split on the morning of Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 11th 2019. An investor that had 100 shares of Rexahn Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

Has Rexahn Pharmaceuticals been receiving favorable news coverage?

News stories about REXN stock have trended very positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Rexahn Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Rexahn Pharmaceuticals
.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 10,100 shares, a decrease of 30.3% from the June 30th total of 14,500 shares. Based on an average daily trading volume, of 60,000 shares, the short-interest ratio is presently 0.2 days. Currently, 0.3% of the shares of the company are sold short.
View Rexahn Pharmaceuticals' Current Options Chain
.

Who are some of Rexahn Pharmaceuticals' key competitors?

What other stocks do shareholders of Rexahn Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SLS International (SLS), Novavax (NVAX), Dynavax Technologies (DVAX), AcelRx Pharmaceuticals (ACRX), CytRx (CYTR), Biopharmx (BPMX) and Madrigal Pharmaceuticals (MDGL).

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the following people:
  • Douglas J. Swirsky, President, CEO, CFO, Secretary & Director
  • D J Kim, Vice President, Head-Research & Development
  • Lisa M. Nolan, Chief Business Officer

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the NASDAQ under the ticker symbol "REXN."

Who are Rexahn Pharmaceuticals' major shareholders?

Rexahn Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.40%). Company insiders that own Rexahn Pharmaceuticals stock include Ben Gil Price, Charles Beever, Douglas J Swirsky and Lisa Nolan.
View institutional ownership trends for Rexahn Pharmaceuticals
.

Which major investors are buying Rexahn Pharmaceuticals stock?

REXN stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Rexahn Pharmaceuticals stock in the last two years include Ben Gil Price, Charles Beever, Douglas J Swirsky, and Lisa Nolan.
View insider buying and selling activity for Rexahn Pharmaceuticals
.

How do I buy shares of Rexahn Pharmaceuticals?

Shares of REXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of REXN stock can currently be purchased for approximately $2.58.

How big of a company is Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals has a market capitalization of $10.37 million. Rexahn Pharmaceuticals employs 10 workers across the globe.

What is Rexahn Pharmaceuticals' official website?

The official website for Rexahn Pharmaceuticals is www.rexahn.com.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company can be reached via phone at 240-268-5300 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.